Q-omics provides the consensus-scored MTCO1P40 profile across patient tissues and cancer cell-line models. MTCO1P40 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MTCO1P40 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, MTCO1P40 RNA expression shows 15,404 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where MTCO1P40 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTCO1P40 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTCO1P40 survival associations across molecular data types. MTCO1P40 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTCO1P40 RNA expression–survival associations across cancer types. High MTCO1P40 expression shows unfavorable associations in SKCM, UCS and BRCA, but favorable associations in ACC, PAAD and THCA. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MTCO1P40 RNA expression.
This table summarizes MTCO1P40 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MTCO1P40. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTCO1P40 shows lower tumor expression in HNSC, LUSC, KIRP, KIRC and PAAD and higher tumor expression in KICH. The HNSC box plot shows higher MTCO1P40 RNA expression in normal versus tumor tissue (log2 FC = −0.986, t-test p < 0.001).
This table shows molecular features associated with MTCO1P40 in patient tissues and cancer cell lines. In patient samples, MTCO1P40 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
